Plasma concentrations of three methylated arginines,endogenous nitric oxide synthase inhibitors, in schizophrenic patients undergoing antipsychotic drug treatment
Plasma concentrations of three methylated arginines,endogenous nitric oxide synthase inhibitors, in schizophrenic patients undergoing antipsychotic drug treatment
复制标题
接受抗精神病药物治疗的精神分裂症患者中三甲基化精氨酸（内源性一氧化氮合酶抑制剂）的血浆浓度
DOI：
10.1016/j.psychres.2016.02.029
复制
发表时间：
2016
影响因子：
11.3
通讯作者：
Hiroshi Homma
中科院分区：
文献类型：
--
作者：
Satoko Nonaka-Hashida;Masae Sekine;Yuji Ozeki ;Kumiko Fujii;Kazufumi Akiyama;Kazutaka Shimoda;Makoto Tsunoda;Masumi Katane;Yasuaki Saitoh;Tetsuya Miyamoto;Hiroshi Homma
三种甲基化精氨酸（内源性一氧化氮合酶抑制剂）的血浆浓度未在精神分裂症患者中进行研究。本研究的目的是测定56名男性和45名女性精神分裂症患者接受抗精神病药物治疗时血浆中NG-单甲基-L-精氨酸（l-NMMA）、NG，NG-二甲基-L-精氨酸（ADMA）、NG，NG '-二甲基-L-精氨酸（SDMA）和l-精氨酸的浓度，并与39名男性和24名女性健康对照者进行比较。用我们以前报道过的高效液相色谱荧光检测法测定血浆中甲基化精氨酸和L-精氨酸的浓度。精神分裂症患者血清中甲基化精氨酸水平略高于正常对照组，l-精氨酸水平及l-精氨酸/（ADMA+ l-NMMA）比值高于正常对照组。据认为，精神分裂症患者的药物治疗可以降低由疾病增加的甲基化精氨酸水平，并增加精氨酸水平，从而引起一氧化氮（NO）生物利用度的改善。
Plasma concentration of three methylated arginines, endogenous nitric oxide synthase inhibitors, is not studied in schizophrenic patients. The purpose of this study was to determine plasma concentrations ofNG-monomethyl-l-arginine (l-NMMA),NG,NG-dimethyl-l-arginine (ADMA),NG,NG’-dimethyl-l-arginine (SDMA), andl-arginine in 56 male and 45 female schizophrenic patients undergoing antipsychotic drug treatment versus those of 39 male and 24 female healthy controls. Plasma concentrations of methylated arginines andl-arginine were measured using newly developed high performance liquid chromatography with fluorescence detection which we previously reported. Methylated arginine levels were slightly but significantly higher in schizophrenic patients.l-Arginine levels and thel-arginine/(ADMA+l-NMMA) ratio were higher in schizophrenic patients than in healthy controls. It is considered that pharmacological treatment of schizophrenic patients may lower methylated arginine levels that are increased by the disease, and increasel-arginine levels, eliciting an improvement in nitric oxide (NO) bioavailability.